ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,631.22
0.28%
Dow Jones
40,211.72
0.53%
US Dollar vs MXN
17.74025
0.05%
Brent Oil
83.355
-1.17%
Bitcoin
63,524.09
-2.06%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Compugen Ltd (CGEN)

  7. Compugen Ltd (CGEN) Noticias

CGEN

Compugen (CGEN)

Compugen Ltd
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:CGEN
FechaHoraFuenteTítuloSímboloCompañía
06/12/202206:00PR Newswire (US)Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Durable Anti-Tumor Activity and Immune Activation in Patients with Platinum Resistant Ovarian CancerNASDAQ:CGENCompugen Ltd
02/12/202206:01Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:CGENCompugen Ltd
01/12/202206:00PR Newswire (US)Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Anti-Tumor Activity and Immune Activation in Platinum Resistant Ovarian Cancer PatientsNASDAQ:CGENCompugen Ltd
29/11/202206:00PR Newswire (US)Compugen to Participate in the JMP Securities Hematology and Oncology SummitNASDAQ:CGENCompugen Ltd
20/11/202223:25TipRanksJMP Securities Sticks to Its Buy Rating for Compugen (CGEN)NASDAQ:CGENCompugen Ltd
16/11/202206:00PR Newswire (US)Compugen to Receive Milestone Payment Triggered by AstraZeneca's Phase 2 Initiation of PD-1/TIGIT BispecificNASDAQ:CGENCompugen Ltd
14/11/202206:00PR Newswire (US)Compugen Reports Third Quarter 2022 ResultsNASDAQ:CGENCompugen Ltd
09/11/202222:26TipRanksSVB Securities Sticks to Its Buy Rating for Compugen (CGEN)NASDAQ:CGENCompugen Ltd
08/11/202206:00PR Newswire (US)Compugen to Participate in the Stifel Healthcare ConferenceNASDAQ:CGENCompugen Ltd
07/11/202207:00PR Newswire (US)Compugen's COM701 (anti-PVRIG) Induces Potent Immune Activation in MSS-CRC PatientsNASDAQ:CGENCompugen Ltd
07/11/202207:00PR Newswire (US)Compugen's COM701 (anti-PVRIG) in Combination with Nivolumab Demonstrates Preliminary Anti-Tumor Activity and Potent Immune Activation in Metastatic MSS-CRC PatientsNASDAQ:CGENCompugen Ltd
02/11/202206:00PR Newswire (US)Compugen Announces Receipt of Nasdaq Delisting NoticeNASDAQ:CGENCompugen Ltd
31/10/202206:00PR Newswire (US)Compugen to Release Third Quarter 2022 Results on Monday, November 14, 2022NASDAQ:CGENCompugen Ltd
26/10/202206:00PR Newswire (US)Compugen to Present New Clinical Data at ESMO-IONASDAQ:CGENCompugen Ltd
06/10/202206:00PR Newswire (US)Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022NASDAQ:CGENCompugen Ltd
22/09/202206:00PR Newswire (US)Compugen Letter to ShareholdersNASDAQ:CGENCompugen Ltd
12/09/202206:00PR Newswire (US)Compugen Announces Appointment of Alberto Sessa as Chief Financial OfficerNASDAQ:CGENCompugen Ltd
07/09/202206:00PR Newswire (US)Compugen to Participate in Upcoming Fierce Biotech SummitNASDAQ:CGENCompugen Ltd
24/08/202206:00PR Newswire (US)Compugen Expands anti-PVRIG COM701 Patent Portfolio with New Composition of Matter and Use Patent in JapanNASDAQ:CGENCompugen Ltd
23/08/202211:35TipRanksTruist Financial Sticks to Its Buy Rating for Compugen (CGEN)NASDAQ:CGENCompugen Ltd
08/08/202206:00PR Newswire (US)Compugen Expands anti-PVRIG COM701 Intellectual Property PortfolioNASDAQ:CGENCompugen Ltd
07/08/202223:35TipRanksJMP Securities Remains a Buy on Compugen (CGEN)NASDAQ:CGENCompugen Ltd
04/08/202206:41Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:CGENCompugen Ltd
04/08/202206:00PR Newswire (US)Compugen Reports Second Quarter 2022 ResultsNASDAQ:CGENCompugen Ltd
21/07/202206:00PR Newswire (US)Compugen to Release Second Quarter Results on Thursday, August 4, 2022NASDAQ:CGENCompugen Ltd
27/06/202206:00PR Newswire (US)Compugen to Present at Upcoming Industry ConferencesNASDAQ:CGENCompugen Ltd
01/06/202206:00PR Newswire (US)Compugen to Present at Upcoming Investor ConferencesNASDAQ:CGENCompugen Ltd
17/05/202200:05TipRanksJMP Securities Thinks Compugen’s Stock is Going to RecoverNASDAQ:CGENCompugen Ltd
16/05/202206:00PR Newswire (US)Compugen Reports First Quarter 2022 ResultsNASDAQ:CGENCompugen Ltd
10/05/202206:00PR Newswire (US)Compugen Announces CFO DepartureNASDAQ:CGENCompugen Ltd
 Showing the most relevant articles for your search:NASDAQ:CGEN

Su Consulta Reciente

NYSE
KO
Coca Cola
AMEX
SPY
SPDR S&P 500
NASDAQ
NVDA
NVIDIA
PM
XAUUSD
Gold vs US Dollar
USOTC
RHHBY
Roche (QX)
NYSE
DIS
Walt Disney
USOTC
BASFY
BASF (QX)
CCOM
US30
US 30
NYSE
CVX
Chevron
NASDAQ
TSLA
Tesla
FX
EURUSD
Euro vs US Dollar
NYSE
JPM
JP Morgan Chase
COIN
SOLUSD
Solana
AMEX
XLV
Health Care Select Sector
NYSE
BAC
Bank of America
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados